Skip to Main Content

Author Details

Ming Li
Princess Margaret Cancer Centre, University Health Network
2003
28
15
PMIDPaper TitleJournal TitlePublished Year
36214668Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non-Small Cell Lung Cancer.Mol Cancer Res2023
36535627Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model.J Thorac Oncol2023
34648945Lung Cancer Driven by BRAF<sup>G469V</sup> Mutation Is Targetable by EGFR Kinase Inhibitors.J Thorac Oncol2022
35383171Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes.Nat Commun2022
36439025Optimizing Drug Response Study Design in Patient-Derived Tumor Xenografts.Cancer Inform2022
32521388BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.Lung Cancer2020
31694835Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer.Clin Cancer Res2020
32903271Cancer proteome and metabolite changes linked to SHMT2.PLoS One2020
32447118EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models.Lung Cancer2020
31383733CD45<sup>+</sup>CD326<sup>+</sup> Cells are Predictive of Poor Prognosis in Non-Small Cell Lung Cancer Patients.Clin Cancer Res2019
30093452Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in <i>PIK3CA</i>-Mutant Lung Squamous Cell Carcinoma.Clin Cancer Res2018
27683181Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma.Clin Cancer Res2017
29156674Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts.Oncotarget2017
27750381Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.Int J Cancer2017
26926157Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.Clin Lung Cancer2016
27613526An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.J Thorac Oncol2016
26095073Patient-derived tumor xenograft models established from samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration.Lung Cancer2015
26124487Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.J Clin Oncol2015
25429762Integrated omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact.Nat Commun2014
22617243Characterization of lymphomas developing in immunodeficient mice implanted with primary human non-small cell lung cancer.J Thorac Oncol2012
21081655The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.Clin Cancer Res2011
20537791Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach.Cancer Lett2010
20019837Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells.Neoplasia2009
18192688Gab1 but not Grb2 mediates tumor progression in Met overexpressing colorectal cancer cells.Carcinogenesis2008
18048091Neither ovariectomy nor progestin treatment prevents endometrial neoplasia in pten+/- mice.Gynecol Oncol2008
17600088Integrin alpha 11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells.Proc Natl Acad Sci U S A2007
15958547In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis.Cancer Res2005
12651912Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo.Mol Cancer Res2003
  • 1 - 28 of 28

Recommended Authors

Kimberley Avila
University of Texas Southwestern Medical Center
Career Start Year 2017
Number of shared co-authors 0
Margaret Soucheray
J. David Gladstone Institutes
Career Start Year 2012
Number of shared co-authors 1
Victor Olivas
University of California san francisco
Career Start Year 2012
Number of shared co-authors 0
Yisong Wang
Lombardi Comprehensive Cancer Center, Georgetown University
Career Start Year 2010
Number of shared co-authors 0
Chad V Pecot
University of North Carolina at Chapel Hill
Career Start Year 2009
Number of shared co-authors 2
Jaya Sangodkar
University of Michigan ann arbor
Career Start Year 2008
Number of shared co-authors 0
John T Poirier
Laura and Isaac Perlmutter Cancer Center
Career Start Year 2007
Number of shared co-authors 4
Martin L Sos
University of Cologne, Faculty of Medicine and University Hospital Cologne
Career Start Year 2005
Number of shared co-authors 1
Jalna Meens
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2004
Number of shared co-authors 4
Elena Ivanova
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 2
Kristopher K Frese
Cancer Research UK Manchester Institute, University of Manchester
Career Start Year 2003
Number of shared co-authors 0
Trudy G Oliver
Duke University
Career Start Year 2003
Number of shared co-authors 0
Lixia Diao
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 0
Trever G Bivona
University of California san francisco
Career Start Year 2002
Number of shared co-authors 1
Andrea Bertotti
Candiolo Cancer Institute - FPO IRCCS
Career Start Year 2000
Number of shared co-authors 0
Benjamin Solomon
Peter MacCallum Cancer Centre
Career Start Year 2000
Number of shared co-authors 7
Eric A Collisson
University of California san francisco
Career Start Year 1999
Number of shared co-authors 0
Collin M Blakely
University of California san francisco
Career Start Year 1998
Number of shared co-authors 1
Peter S Hammerman
Novartis Institutes for BioMedical Research
Career Start Year 1996
Number of shared co-authors 2
Vincent A Miller
Injury Prevention Research Center, University of North Carolina
Career Start Year 1994
Number of shared co-authors 3
Gregory J Riely
Memorial Sloan Kettering Cancer Center
Career Start Year 1994
Number of shared co-authors 3
Michael Peyton
Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center
Career Start Year 1994
Number of shared co-authors 0
Livio Trusolino
Candiolo Cancer Institute - FPO IRCCS
Career Start Year 1993
Number of shared co-authors 1
E Alejandro Sweet-Cordero
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 0
Charles M Rudin
Memorial Sloan Kettering Cancer Center
Career Start Year 1989
Number of shared co-authors 7
David S Schrump
Center for Cancer Research, National Cancer Institute
Career Start Year 1988
Number of shared co-authors 0
Pasi A J??nne
Dana-Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 5
Roy S Herbst
Yale School of Medicine
Career Start Year 1984
Number of shared co-authors 3
David M Jablons
University of California, USA Cardiovascular Research Institute san francisco
Career Start Year 1981
Number of shared co-authors 2
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 1

Collaborators

Ming-Sound Tsao
University Health Network, University of Toronto
Co-authored papers 28
Nhu-An Pham
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 19
Frances A Shepherd
University Health Network, Princess Margaret Cancer Centre
Co-authored papers 15
Geoffrey Liu
The Princess Margaret Cancer Centre/University of Toronto
Co-authored papers 12
Melania Pintilie
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 8
Nadeem Moghal
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 8
Vibha Raghavan
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 6
Shingo Sakashita
National Cancer Center Exploratory Oncology Research & Clinical Trial Center
Co-authored papers 6
Chang-Qi Zhu
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 6
Paul Taylor
Hospital for Sick Children
Co-authored papers 5
Jiefei Tong
Hospital for Sick Children
Co-authored papers 5
Michael F Moran
Hospital for Sick Children, University of Toronto
Co-authored papers 5
Naoki Yanagawa
Yamagata Prefectural Central Hospital
Co-authored papers 5
Roya Navab
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 4
Thomas John
Peter MacCallum Cancer Centre
Co-authored papers 4
Jenna Sykes
St. Michael's Hospital, University of Toronto
Co-authored papers 4
Ni Liu
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Co-authored papers 4
Dennis Wang
Sheffield Institute of Translational Neuroscience, University of Sheffield
Co-authored papers 4
Lucia Kim
Inha University Hospital
Co-authored papers 4
Ghassan Allo
Henry Ford Hospital
Co-authored papers 3
Igor Jurisica
Schroeder Arthritis Institute
Co-authored papers 3
Thomas Kislinger
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Co-authored papers 3
Michael R Johnston
Dalhousie University
Co-authored papers 3
Christine To
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 3
Cynthia Hawkins
The Hospital for Sick Children
Co-authored papers 2
Lakshmi Muthuswamy
Harvard Medical School
Co-authored papers 2
Shirley Tam
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 2
Thomas K Waddell
Toronto General Hospital
Co-authored papers 2
Vladimir Ignatchenko
Margaret Cancer Center
Co-authored papers 2
Lei Li
Hospital for Sick Children
Co-authored papers 2
Release 1.2